Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

2,676.00p
   
  • Change Today:
    -8.00p
  • 52 Week High: 6,070.00
  • 52 Week Low: 2,234.00
  • Currency: UK Pounds
  • Shares Issued: 65.77m
  • Volume: 16,688
  • Market Cap: £1,760.01m
  • RiskGrade: 128

Fundamentals - based on IFRS

  £ (Millions) £ (Millions) £ (Millions) £ (Millions) £ (Millions)
Income Statement 31-Dec-21 31-Dec-20 31-Dec-19 31-Dec-18 31-Dec-17
Continuing Operations          
Revenue 281.20 285.70 270.70 238.80 238.60
Operating Profit/(Loss) 23.90 34.20 28.10 (6.30) 14.30
Profit Before Tax 24.40 37.40 30.40 (6.80) 14.30
Profit After Tax 18.90 29.00 24.10 (7.10) 42.60
Discontinued Operations          
Profit After Tax n/a n/a n/a n/a n/a
PROFIT FOR THE PERIOD 18.90 29.00 24.10 (7.10) 42.60
           
Continuing EPS          
Earnings per Share - Basic 30.40p 46.40p 36.50p (11.70p) 69.00p
Earnings per Share - Diluted 30.20p 46.00p 36.30p (11.00p) 67.80p
Earnings per Share - Adjusted 42.40p 55.30p 43.50p 35.80p 40.90p
Continuing and Discontinued EPS          
Earnings per Share - Basic 30.40p 46.40p 36.50p (11.70p) 69.00p
Earnings per Share - Diluted 30.20p 46.00p 36.30p (11.00p) 67.80p
Earnings per Share - Adjusted 42.40p 55.30p 43.50p 35.80p 40.90p
Dividend per Share 10.30p 10.30p 9.40p 8.90p 8.10p
  £ (Millions) £ (Millions) £ (Millions) £ (Millions) £ (Millions)
Balance Sheet 31-Dec-21 31-Dec-20 31-Dec-19 31-Dec-18 31-Dec-17
Total Non-Current Assets 646.90 598.20 607.30 615.00 552.70
Net Current Assets cn/a cn/a cn/a cn/a cn/a
Total Assets 896.20 827.10 818.50 802.80 775.00
Total Liabilities 389.80 343.60 338.60 314.40 351.80
Net Assets 506.40 483.50 479.90 488.40 423.20
           
Shareholders Funds 509.10 485.80 481.00 486.10 419.10
Minority Interests/Other Equity (2.70) (2.30) (1.10) 2.30 4.10
Total Equity 506.40 483.50 479.90 488.40 423.20

Key

* GAAP

a. Includes discontinued activities

b. Including assets due in more than one year

c. Not disclosed under IFRS

d. Total fixed assets

e. Includes borrowings

f. Included in cash flow from operating activities under IFRS

g. Included in net cash from investing activities under IFRS

h. Pre-tax

i. Capital expenditure

j. Based on operating cash flow before tax

k. Issue of ordinary shares

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: Forecast figures based on normalised accounts.

 

Top of Page